Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial

Peter E. Schwartz, Joseph T. Chambers, Ernest I. Kohorn, Setsuko K. Chambers, Hervey Weitzman, Irene M. Voynick, Neil Maclusky, Frederick Naftolin

Research output: Contribution to journalArticle

58 Scopus citations

Abstract

One hundred patients with Stage III and IV epithelial ovarian cancer participated in a prospective randomized study to determine whether the addition of tamoxifen, an estrogen agonist‐antagonist, to standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum) would significantly improve survival. Fifty‐one patients received the standard cytotoxic chemotherapy and 49 received tamoxifen as well. No significant difference in overall or progression‐free survival between these two patient groups was observed. Cytosol steroid receptor determinations were performed on tumor samples from 72 patients. No correlation was evident between therapy and cytosol estrogen and progestin receptor content of the tumors. This study suggests that the strategy of combining an antiproliferative, hormonally active agent with cytotoxic chemotherapy for management of advanced ovarian cancer may be inappropriate.

Original languageEnglish (US)
Pages (from-to)1074-1078
Number of pages5
JournalCancer
Volume63
Issue number6
DOIs
StatePublished - Mar 15 1989
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial'. Together they form a unique fingerprint.

  • Cite this